Product description
Valpam 5
Diazepam 5mg, 50 tablets
Batch CP218
Expiry date Jan 2021
ARTG Number 80811
Diazepam 5mg, 50 tablets
Batch CP218
Expiry date Jan 2021
ARTG Number 80811
See a list of details to help identify the product
Reason the product is recalled
One batch of Valpam 5 (batch CP218) may contain blister strips with a white Valpam 2mg tablet, instead of a yellow Valpam 5mg tablet.
The hazards to consumers
Patients may not receive the correct dose.
What consumers should do
If patients have Valpam 5 from batch number CP218, blister strips should be inspected prior to use, in order to ensure that all of the tablets in a given blister are light yellow in colour and marked with ‘DZ 5’ on one side. This marking will only be visible if the tablet happens to be loaded into the blister facing upwards, which is normal for all blistered tablets. In the event no anomalies are found, the product may continue to be used as normal and no further action is necessary. In the unlikely event a blister is found to contain a white‐to‐off white tablet amongst the other yellow tablets, these blisters are affected and should not be used. Consumers are advised to return any unopened affected blisters to the place of purchase for a refund or replacement.
Further information is available from https://www.tga.gov.au/alert/valpam-5-diazepam-5-mg-tablets or from Arrow Pharma on 1800 941 148.
Further information is available from https://www.tga.gov.au/alert/valpam-5-diazepam-5-mg-tablets or from Arrow Pharma on 1800 941 148.
Details to help identify the product
Supplier running the recall
Who sold the product
Pharmacies
Identifying numbers
Barcode number
9350299000887
Other identifying numbers
AUST R 80811
Dates available for sale
-
Where the product was sold
Nationally
Responsible regulators
Regulators are established or appointed by government. They enforce regulations and rules.
Quote PRA number 2018/16827 when contacting a regulator about this recall.
Recall and remedy questions
Contact the Therapeutic Goods Administration if you have:
- a question about the remedy being offered to you by the business that is responsible for managing this recall, or
- concerns about the way the business is managing this recall.